| Source: |
| Type: |
| Tumor cell migration is a critical process in cancer progression and metastasis, which is the spread of cancer cells from the primary tumor to distant sites in the body. |
| 9246- | ISO, IH, | Isorhamnetin inhibits migration and promotes apoptosis via modulation of oxidative stress, mitochondrial dysfunction, and the TIGIT/CD155 axis in 4T1 breast cancer cells |
| - | in-vitro, | BC, | 4T1 |
| 9244- | ISO, IH, | Isorhamnetin inhibits bladder cancer progression by mediating glycolysis through targeting the SRC/PI3K/Akt axis |
| - | in-vitro, | Bladder, | 5637 |
| 9242- | ISO, IH, | Isorhamnetin Induces Melanoma Cell Apoptosis via the PI3K/Akt and NF- κ B Pathways |
| - | vitro+vivo, | Melanoma, | B16-BL6 |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 7730- | isoFl, | Anticancer Potential of Isoflavones: A Narrative Overview of Mechanistic Insights and Experimental Evidence from the Past Ten Years |
| - | Review, | Var, | NA |
| 7859- | isoO, | Isoorientin induces apoptosis, decreases invasiveness, and downregulates VEGF secretion by activating AMPK signaling in pancreatic cancer cells |
| - | in-vitro, | PC, | PANC1 |
| 7869- | isoO, | Apoptosis induction and inhibition of invasion and migration in gastric cancer cells by Isoorientin studied using network pharmacology |
| - | in-vitro, | GC, | HGC27 |
| 7792- | ISQ, | Isoquercitrin suppresses colon cancer cell growth in vitro by targeting the Wnt/β-catenin signaling pathway |
| - | in-vitro, | CRC, | SW48 | - | in-vitro, | CRC, | DLD1 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | IEC-18 |
| 7845- | ISQ, | Isoquercitrin, ingredients in Tetrastigma hemsleyanum Diels et Gilg, inhibits hepatocyte growth factor/scatter factor-induced tumor cell migration and invasion |
| - | vitro+vivo, | Bladder, | NBT-II |
| 9177- | ITCs, | SFN, | Dietary Isothiocyanates: Novel Insights into the Potential for Cancer Prevention and Therapy |
| - | Review, | Var, | NA |
| 7997- | itraC, | Anti-fungal drug itraconazole exerts anti-cancer effects in oral squamous cell carcinoma via suppressing Hedgehog pathway |
| - | vitro+vivo, | SCC, | NA |
| 8014- | itraC, | Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer |
| - | vitro+vivo, | NSCLC, | NA |
| 8037- | IVM, | Ivermectin inhibits tumor metastasis by regulating the Wnt/β-catenin/integrin β1/FAK signaling pathway |
| - | in-vitro, | Var, | NA |
| 8043- | IVM, | Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in oesophageal squamous cell carcinoma |
| - | vitro+vivo, | ESCC, | KYSE-30 | - | in-vitro, | ESCC, | KYSE70 | - | in-vitro, | ESCC, | KYSE150 |
| 8045- | IVM, | Ivermectin induces cell cycle arrest and apoptosis of HeLa cells via mitochondrial pathway |
| - | in-vitro, | Cerv, | HeLa |
| 8050- | IVM, | doxoR, | Repurposing Ivermectin to augment chemotherapy's efficacy in osteosarcoma |
| - | in-vitro, | OS, | NA |
| 7892- | IVT, | Isovitexin attenuates tumor growth in human colon cancer cells through the modulation of apoptosis and epithelial-mesenchymal transition via PI3K/Akt/mTOR signaling pathway |
| - | in-vitro, | Nor, | HCEC 1CT | - | in-vivo, | Colon, | NA |
| 7965- | JG, | Mechanistic investigation of Juglone (5-hydroxy-1,4-naphthoquinone) as an anti-cancer agent in human colorectal cancer HCT116 and HT-29 cell lines |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT-29 |
| 8007- | JG, | Juglone reduces growth and migration of U251 glioblastoma cells and disrupts angiogenesis |
| - | in-vitro, | GBM, | U251 |
| 1924- | JG, | Juglone triggers apoptosis of non-small cell lung cancer through the reactive oxygen species -mediated PI3K/Akt pathway |
| - | in-vitro, | Lung, | A549 |
| 1920- | JG, | TQ, | PLB, | Natural quinones induce ROS-mediated apoptosis and inhibit cell migration in PANC-1 human pancreatic cancer cell line |
| - | in-vitro, | PC, | PANC1 |
| 8089- | KAE, | Kaempferol impairs aerobic glycolysis against melanoma metastasis via inhibiting the mitochondrial binding of HK2 and VDAC1 |
| - | in-vitro, | Melanoma, | A375 | - | in-vitro, | Melanoma, | B16-F10 |
| - | in-vitro, | Melanoma, | A375 |
| 8071- | KAE, | Cellular reprogramming and signaling control by kaempferol in colorectal cancer |
| - | Review, | CRC, | NA |
| 8059- | KAE, | Kaempferol Inhibits Cervical Cancer Cells by Inducing Apoptosis and Autophagy via Inactivation of the PI3K/AKT/mTOR Signaling Pathway |
| - | in-vitro, | Cerv, | KB |
| 8064- | KAE, | Kaempferol Inhibits Pancreatic Cancer Cell Growth and Migration through the Blockade of EGFR-Related Pathway In Vitro |
| - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | SNU-213 |
| 8067- | KAE, | Cisplatin, | Kaempferol Induces Cell Death and Sensitizes Human Head and Neck Squamous Cell Carcinoma Cell Lines to Cisplatin |
| - | in-vitro, | HNSCC, | NA |
| 8075- | KAE, | QC, | Systematic review on anticancer potential of Kaempferol and quercetin against lung, breast, and colorectal cancers with emphasis on in vitro and in vivo studies |
| - | Review, | Var, | NA |
| 9065- | L-THE, | L-Theanine inhibits cancer stem cell-mediated chemoresistance in lung cancer by regulating STAT3/NOTCH1-BMAL1 signaling |
| - | in-vitro, | Lung, | NA |
| 9002- | L-THE, | Effects of theanine on growth of human lung cancer and leukemia cells as well as migration and invasion of human lung cancer cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | AML, | K562 |
| 9008- | L-THE, | Theanine and cancer: A systematic review of the literature |
| - | Review, | Var, | NA |
| 9006- | L-THE, | Theanine from tea and its semi-synthetic derivative TBrC suppress human cervical cancer growth and migration by inhibiting EGFR/Met-Akt/NF-κB signaling |
| - | vitro+vivo, | Cerv, | HeLa |
| 9004- | L-THE, | L-theanine suppresses the metastasis of prostate cancer by downregulating MMP9 and Snail |
| - | vitro+vivo, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 8165- | LapC, | Lapachol interferes with the cell cycle and inhibits proliferation and migration of bladder tumor cells with effects on ncRNA expression |
| - | in-vitro, | Bladder, | RT4 |
| 8175- | Las, | Lasiodin Inhibits Proliferation of Human Nasopharyngeal Carcinoma Cells by Simultaneous Modulation of the Apaf-1/Caspase, AKT/MAPK and COX-2/NF-κB Signaling Pathways |
| - | in-vitro, | NPC, | NA |
| 8237- | LCA, | Role of Licochalcone A in Potential Pharmacological Therapy: A Review |
| - | Review, | Var, | NA |
| 8243- | LCA, | Licochalcone A Inhibits Cellular Motility by Suppressing E-cadherin and MAPK Signaling in Breast Cancer |
| - | in-vitro, | BC, | MDA-MB-231 |
| 8251- | LCA, | Licochalcone A inhibits the migration and invasion of human lung cancer cells via inactivation of the Akt signaling pathway with downregulation of MMP-1/-3 expression |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 |
| 8275- | LCA, | Licochalcone A inhibits glioma migration, invasion, and growth by triggering mitochondrial dysfunction and ROS-mediated oxidative damage |
| - | vitro+vivo, | GBM, | NA |
| 8235- | LCA, | Anticancer effects of licochalcones: A review of the mechanisms |
| - | Review, | Var, | NA |
| 8232- | LCA, | Licochalcone A induces G2/M phase arrest and apoptosis via regulating p53 pathways in esophageal cancer: In-vitro and in-vivo study |
| - | vitro+vivo, | ESCC, | NA |
| 8222- | LCA, | Licochalcone A Induces Cholangiocarcinoma Cell Death Via Suppression of Nrf2 and NF-κB Signaling Pathways |
| - | in-vitro, | CCA, | KKU-100 | - | in-vitro, | CCA, | KKU-213 | - | in-vitro, | CCA, | KKU-214 | - | in-vitro, | CCA, | KKU-156 | - | in-vitro, | 0-Reserved, | KKU-452 |
| 8338- | LDN, | Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway |
| - | vitro+vivo, | Cerv, | HeLa | - | in-vitro, | Cerv, | SiHa |
| 8339- | LDN, | Low-dose naltrexone inhibits the epithelial-mesenchymal transition of cervical cancer cells in vitro and effects indirectly on tumor-associated macrophages in vivo |
| - | in-vivo, | Cerv, | HeLa |
| 8291- | LE, | Glycyrrhizic acid inhibits leukemia cell growth and migration via blocking AKT/mTOR/STAT3 signaling |
| - | vitro+vivo, | AML, | TF1 |
| 8290- | LE, | Licoricidin, an Active Compound in the Hexane/Ethanol Extract of Glycyrrhiza uralensis, Inhibits Lung Metastasis of 4T1 Murine Mammary Carcinoma Cells |
| - | vitro+vivo, | Pca, | DU145 |
| 8288- | LE, | 18 β-glycyrrhetinic acid exhibits potent antitumor effects against colorectal cancer via inhibition of cell proliferation and migration |
| - | vitro+vivo, | CRC, | NA |
| 8279- | LE, | 18β-Glycyrrhetinic Acid Has Anti-Cancer Effects via Inducing Apoptosis and G2/M Cell Cycle Arrest, and Inhibiting Migration of A549 Lung Cancer Cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H23 | - | in-vitro, | Lung, | H460 |
| 1266- | LE, | Glycyrrhizin suppresses epithelial-mesenchymal transition by inhibiting high-mobility group box1 via the TGF-β1/Smad2/3 pathway in lung epithelial cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | BEAS-2B |
| 8143- | LF, | Lactoferrin mediates epithelial-mesenchymal transformation by regulating the PI3K/AKT/mTOR pathway to inhibit nasopharyngeal carcinoma metastasis |
| - | in-vitro, | NPC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:326 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid